Application of tribulus terrestris saponin and protodioscin, anti-inflammatory composition and emulsion
Through the anti-inflammatory composition of terrestrial terrestrial saponin and prodiphyllon, the synergistic effect of the anti-inflammatory field is solved, and significant effects in anti-inflammatory and skin protection are achieved.
Patent Information
- Application Number
- CN202411067372.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-06
- Publication Date
- 2024-11-19
AI Technical Summary
In existing studies, the application range of terrestrial terrestris saponins and prodiphytosinosaponins is limited and lacks effective expansion in anti-inflammatory aspects.
An anti-inflammatory composition of terrestrial terrestrial saponin and prodiphyllin is provided, and is used to prepare anti-inflammatory preparations for synergistic inhibition through different mass ratios (1:1-10,000, preferably 0.01-1:1.7648-176.48). NO is produced and applied in skin protection preparations and cosmetics.
The synergistic effect of terrestrial terrestrial saponin and prodiphyllonin composition in anti-inflammatory aspects has been achieved, significantly improved the anti-inflammatory effect, and inhibited NO at low concentrations. It is suitable for skin protection preparations and cosmetics, and has excellent anti-inflammatory functions. .
Smart Images

Figure CN118976038A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of anti-inflammatory treatment, and in particular to uses of tribulus terrestris saponin and protodioscin, and an anti-inflammatory composition and emulsion. Background Art
[0002] Tiliroside is a flavonoid that can be isolated from Tribulus terrestris L., and existing studies have found that it can be used to inhibit non-pathogenic mycobacteria.
[0003] Protodioscin is a compound that can be extracted from the Dioscorea plant of the Dioscorea family. Existing studies have found that it can be used to fight cancer and promote movement and sexual function.
[0004] Research on the efficacy of tribulus saponins and protodioscin in other aspects is still limited. Therefore, how to expand the application of tribulus saponins and protodioscin is an urgent problem to be solved. Summary of the invention
[0005] One purpose of the embodiments of the present application is to solve at least one problem in the above background and provide corresponding beneficial effects.
[0006] Another purpose of the embodiments of the present application is to provide a use of Tribulus terrestris saponin and protodioscin, an anti-inflammatory composition and an emulsion, which can be used to solve the problem of anti-inflammatory.
[0007] The embodiments of the present application mainly achieve the aforementioned objectives through the following technical solutions.
[0008] In one aspect, the embodiments of the present application provide a use of protodioscin for anti-inflammatory purposes.
[0009] Protodioscin has the structure shown in formula (1):
[0010] Structural formula (1):
[0011] Optionally, the present application embodiment provides a use of protodioscin for synergistic anti-inflammatory effects with tribulus terrestris saponin, wherein the mass ratio of tribulus terrestris saponin to protodioscin is 1:1 to 10000. Preferably, it is 0.01 to 1:1.7648 to 176.48.
[0012] Optionally, an embodiment of the present application provides a use of protodioscin for synergizing with Tribulus terrestris saponin to inhibit NO production.
[0013] It is understandable that the embodiments of the present application also provide a use of protodioscin in the preparation of an anti-inflammatory preparation.
[0014] Optionally, the anti-inflammatory formulation is an anti-inflammatory composition.
[0015] In yet another aspect, the embodiments of the present application provide a use of Tribulus terrestris saponin for anti-inflammatory purposes.
[0016] Tribulus terrestris saponin has the structure shown in formula (2):
[0017] Structural formula (2):
[0018] Optionally, the present application embodiment provides a use of tribulus terrestris saponin for synergistic anti-inflammatory effect with protodioscin, wherein the mass ratio of tribulus terrestris saponin to protodioscin is 1:1 to 10000. Preferably, it is 0.01 to 1:1.7648 to 176.48.
[0019] Optionally, an embodiment of the present application provides a use of Tribulus terrestris saponin for synergizing with protodioscin to inhibit NO production.
[0020] It is understandable that the embodiments of the present application also provide a use of tribulus saponin in the preparation of an anti-inflammatory preparation.
[0021] Optionally, the anti-inflammatory formulation is an anti-inflammatory composition.
[0022] In yet another aspect, the embodiments of the present application provide a composition comprising: Tribulus terrestris saponin and protodioscin.
[0023] The combination of tribulus terrestris saponin and protodioscin can produce a synergistic effect. Therefore, the composition containing tribulus terrestris saponin and protodioscin can also have an anti-inflammatory effect and has an anti-inflammatory function.
[0024] In at least one embodiment, the mass ratio of the tribulus terrestris saponin to the protodioscin is 1:1-10000, which is beneficial to improving the anti-inflammatory effect. Preferably, it is 0.01-1:1.7648-176.48.
[0025] In yet another aspect, the embodiments of the present application provide a use of Tribulus terrestris saponin and protodioscin in the preparation of an anti-inflammatory preparation.
[0026] In yet another aspect, the embodiments of the present application provide a use of tribulus terrestris saponin and protodioscin in the preparation of skin protection preparations, cosmetics or medicines.
[0027] Optionally, the skin protection preparation is an external skin preparation.
[0028] In some embodiments, the skin protection preparation is a face cream, sunscreen, milky face cream, facial mask, essence, eye cream, primer, liquid foundation, concealer, lotion, cleanser, toner, softener, firming lotion, lotion or body lotion, etc.
[0029] In yet another aspect, the amount of Tribulus terrestris saponin added to the skin protection preparation is 0.001% to 1%.
[0030] In yet another aspect, the amount of protodioscin added to the skin protection preparation is 0.001% to 1%.
[0031] In yet another aspect, the embodiments of the present application provide an emulsion comprising Tribulus terrestris saponin and protodioscin.
[0032] The beneficial effects of the embodiments of the present invention include:
[0033] In some embodiments, the present application provides a composition, including: tribulus saponin and protodioscin. The combination of tribulus saponin and protodioscin can produce a synergistic effect, so the composition containing tribulus saponin and protodioscin can also have an anti-inflammatory effect.
[0034] In some embodiments, the present application provides a use of Tribulus terrestris saponin and Protodioscin in the preparation of an anti-inflammatory preparation. BRIEF DESCRIPTION OF THE DRAWINGS
[0035] Figure 1 A schematic diagram of cell survival rate at different protodioscin concentrations in Experimental Example 1 of the present application;
[0036] Figure 2 A schematic diagram of cell survival rate at different concentrations of Tribulus terrestris saponin in Experimental Example 1 of the present application;
[0037] Figure 3 A schematic diagram of the color reaction of each group of culture medium supernatant and Griess reagent after incubation at room temperature for 30 minutes in Experimental Example 2 of the present embodiment;
[0038] Figure 4 This is a schematic diagram of the inflammation clearance rate of each group in Experimental Example 2 of the present embodiment. DETAILED DESCRIPTION
[0039] The present invention is further described in detail below in conjunction with the accompanying drawings so that those skilled in the art can implement the invention with reference to the description.
[0040] The terms "first", "second", "third", "fourth", "fifth", "sixth", etc. in the embodiments of the present application are used for descriptive purposes only and should not be understood as indicating or implying relative importance or implicitly indicating the number of the indicated technical features. Therefore, a feature defined as "first", "second", etc. may explicitly or implicitly include at least one of the features.
[0041] Furthermore, the terms "comprises", "comprising", "including" and any variations thereof are intended to cover non-exclusive inclusions. For example, a process, method, system, product or apparatus comprising a series of steps or units is not limited to the listed steps or units, but may optionally include steps or units not listed, or may optionally include other steps or units inherent to the process, method, product or apparatus.
[0042] In addition to the above, it is still necessary to emphasize that the reference to "embodiment" in this article means that the specific features, structures or characteristics described in conjunction with the embodiment may be included in at least one embodiment of the present application. The appearance of this phrase in various places in the specification does not necessarily refer to the same embodiment, nor is it an independent or alternative embodiment that is mutually exclusive with other embodiments. It is explicitly and implicitly understood by those skilled in the art that the embodiments described herein can be combined with other embodiments.
[0043] Unless otherwise specified, the term "LPS" refers to bacterial lipopolysaccharide, whose full English name is lipopolysaccharide.
[0044] Unless otherwise specified, the term "μM" is a concentration unit, representing μmol / L (micromole / liter), and "nM" is also a concentration unit, representing nmol / L (nanomole / liter).
[0045] In one aspect, the embodiments of the present application provide a use of protodioscin for anti-inflammatory purposes.
[0046] Optionally, the present application embodiment provides a use of protodioscin for synergistic anti-inflammatory effects with tribulus terrestris saponin, wherein the mass ratio of tribulus terrestris saponin to protodioscin is 1:1 to 10000. Preferably, it is 0.01 to 1:1.7648 to 176.48.
[0047] Optionally, an embodiment of the present application provides a use of protodioscin for synergizing with Tribulus terrestris saponin to inhibit NO production.
[0048] It is understandable that the embodiments of the present application also provide a use of protodioscin in the preparation of an anti-inflammatory preparation.
[0049] Optionally, the anti-inflammatory formulation is an anti-inflammatory composition.
[0050] In yet another aspect, the embodiments of the present application provide a use of Tribulus terrestris saponin for anti-inflammatory purposes.
[0051] Optionally, the present application embodiment provides a use of tribulus terrestris saponin for synergistic anti-inflammatory effect with protodioscin, wherein the mass ratio of tribulus terrestris saponin to protodioscin is 1:1 to 10000. Preferably, it is 0.01 to 1:1.7648 to 176.48.
[0052] Optionally, an embodiment of the present application provides a use of Tribulus terrestris saponin for synergizing with protodioscin to inhibit NO production.
[0053] It is understandable that the embodiments of the present application also provide a use of Tribulus terrestris saponin in the preparation of an anti-inflammatory preparation.
[0054] Optionally, the anti-inflammatory formulation is an anti-inflammatory composition.
[0055] In yet another aspect, the embodiments of the present application provide a composition comprising: Tribulus terrestris saponin and protodioscin.
[0056] The combination of tribulus terrestris saponin and protodioscin can produce a synergistic effect, so the composition containing tribulus terrestris saponin and protodioscin can also play an anti-inflammatory effect.
[0057] In at least one embodiment, the mass ratio of the tribulus terrestris saponin to the protodioscin is 1:1-10000, which is beneficial to improving the anti-inflammatory effect. Preferably, it is 0.01-1:1.7648-176.48.
[0058] In at least one embodiment, the composition further comprises a solvent.
[0059] In at least one embodiment, the solvent comprises water.
[0060] In yet another aspect, the embodiments of the present application provide a use of Tribulus terrestris saponin and protodioscin in the preparation of an anti-inflammatory preparation.
[0061] Optionally, the anti-inflammatory preparation is used as a skin protection preparation, a cosmetic or a medicine.
[0062] Optionally, the skin protection preparation is selected from any one of facial cream, sunscreen, milky cream, facial mask, essence, eye cream, primer, liquid foundation, concealer, lotion, cleanser, toner, softener, firming lotion, lotion and body lotion.
[0063] In yet another aspect, the embodiments of the present application provide a use of tribulus terrestris saponin and protodioscin in the preparation of skin protection preparations, cosmetics or medicines.
[0064] Optionally, the skin protection preparation is an external skin preparation.
[0065] In some embodiments, the skin protection preparation is a face cream, sunscreen, milky face cream, facial mask, essence, eye cream, primer, liquid foundation, concealer, lotion, cleanser, toner, softener, firming lotion, lotion or body lotion, etc.
[0066] In yet another aspect, the embodiments of the present application provide an emulsion comprising Tribulus terrestris saponin and protodioscin.
[0067] <Verification of the Use of Tribulus Terrestris Saponin and Protodioscin>
[0068] 1. Experimental Materials and Their Sources
[0069] Table 1
[0070]
[0071] 2. Subculture of experimental cells:
[0072] Cell culture: Pour working medium into a T75 culture flask, inoculate mouse mononuclear macrophage leukemia cells on the working medium, and then culture the inoculated mouse mononuclear macrophage leukemia cells under the conditions of a CO2 concentration of 5% and a temperature of 37°C.
[0073] Cell subculture: When the working liquid culture medium of the T75 culture flask turns yellow, the working liquid culture medium of the T75 culture flask can be repeatedly blown and the cells will fall off from the wall. The cells can then be plated to obtain plated cells. The method of plating includes: after the cells fall off the wall, part of the new working liquid culture medium can be directly added to the T75 culture flask, and then the cells can be plated directly in the T75 culture flask, or the original working liquid culture medium of the T75 culture flask can be centrifuged and the cells can be resuspended for plating.
[0074] The following experiments can select experimental materials and subculture cells from the above examples as needed.
[0075] <Experimental Example 1, Cytotoxicity Experiment>
[0076] Experimental Example 1 The cell viability was detected by CCK-8 (English name: Cell Counting Kit-8) kit to determine the sample concentration required for subsequent experiments.
[0077] Experimental Example 1 includes the following steps:
[0078] S101, collecting mouse mononuclear macrophage leukemia cells in the logarithmic growth phase, counting them using a cell counter, plating the cells in a 96-well plate at a cell concentration of 2 w / well, and then culturing them in a cell culture incubator;
[0079] S102. After culturing the cells in a cell culture incubator for 24 hours, the cells were divided into 1 experimental control group and 10 experimental groups, the 10 experimental groups being experimental groups 1-10; the experimental control group was not treated with medication, and experimental groups 1-10 were all treated with medication, and different concentrations of protodioscin test solution, such as 0.01 μM, 0.1 μM, 1 μM, 10 μM, 100 μM, and different concentrations of Tribulus terrestris saponin test solution, such as 0.01 μM, 0.1 μM, 1 μM, 10 μM, 50 μM, were added, respectively. The specific medication treatments are shown in Table 2; then the incubation and culture were continued for 24 hours, and the culture solution of each experimental group was replaced with a CCK8 solution containing CCK-8 at a concentration of 1X;
[0080] Table 2
[0081]
[0082] S103. After continuing to incubate in the cell culture incubator for 2 hours, the absorbance of each group of culture wells was measured using a microplate reader at a detection wavelength of 450 nm and a reference wavelength of 650 nm; it should be understood that during the detection, the culture wells of experimental groups 1-5 contained cells, culture medium and CCK-8 solution treated with corresponding concentrations of protodioscin, the culture wells of experimental groups 6-10 contained cells, culture medium and CCK-8 solution treated with corresponding concentrations of tribulus terrestris saponin, and the culture wells of the experimental control group contained cells, culture medium and CCK-8 solution not treated with protodioscin and tribulus terrestris saponin.
[0083] S104. In addition, a zeroing well is set in the 96-well plate. The zeroing well has no cells and only contains 1X CCK-8 solution, which is used as a control group for calculating the cell survival rate of the experimental control group and the experimental group. The absorbance of the zeroing well of the control group is measured using an ELISA reader at a detection wavelength of 450nm and a reference wavelength of 650nm. It should be understood that during the detection, the zeroing well contains CCK-8 solution and culture medium, but does not contain cells, Tribulus terrestris saponin and protodioscin.
[0084] S105. Calculate the cell survival rates of the experimental control group and the experimental group according to the absorbance measured above. The calculation formula is shown in the following formula (1):
[0085] Formula (1): Cell survival rate = [(OD experimental well - OD zeroing well) / (OD control well - OD zeroing well)] × 100%;
[0086] Among them, the OD experimental well is the absorbance value of the experimental group, the OD control well is the absorbance value of the control group, and the OD zero adjustment well is the absorbance value of the calculated control group.
[0087] Experimental results and analysis of Experimental Example 1:
[0088] The experimental results are shown in Tables 3-4 and Figure 1-2 , Figure 1 A schematic diagram of cell survival rate at different protodioscin concentrations. Figure 2 A schematic diagram of cell survival rate at different concentrations of Tribulus terrestris saponins.
[0089] Table 3
[0090] Protodioscin concentration / μM Cell viability ± standard deviation 0 (experimental control group) 1±0.024 0.01(experimental group 1) 1.019±0.008 0.1 (experimental group 2) 1.001±0.171 1(Experimental group 3) 0.966±0.065 10 (experimental group 4) 0.186±0.033 100 (experimental group 5) -0.044±0.011
[0091] Table 4
[0092] Tribulus terrestris saponin concentration / μM Cell viability ± standard deviation 0 (experimental control group) 1±0.024 0.01(experimental group 6) 0.912±0.053 0.1 (experimental group 7) 0.559±0.135 1(Experimental group 8) 0.524±0.055 10 (experimental group 9) 0.518±0.096 50 (experimental group 10) 0.274±0.079
[0093] According to the above results, it can be seen that protodioscin has no cytotoxicity at a concentration below 1 μM; Tribulus terrestris saponin has no obvious cytotoxicity at a concentration below 0.01 μM.
[0094] It can be determined that in order to ensure normal cell growth, the cell experimental concentration of protodioscin can be selected to be less than or equal to 1 μM, and the cell experimental concentration of tribulus terrestris saponin can be selected to be less than or equal to 10 μM.
[0095] <Experimental Example 2>
[0096] Experimental Example 2 includes the following experimental steps:
[0097] Step S201: Take the subcultured mouse mononuclear macrophage leukemia cells and inoculate them into a cell culture plate (the cell culture plate is a 12-well cell culture plate). Each well of the inoculated cell culture plate contains 2×10 5 cells; then the inoculated cell culture plate was placed in an incubator at 37°C and 5% carbon dioxide concentration for overnight incubation.
[0098] Step S202, after incubation for 24 hours, the cells on the cell culture plate were divided into a negative control group, an LPS stimulation control group and 12 LPS stimulation drug administration groups, wherein the 12 LPS stimulation drug administration groups were: dexamethasone group (positive drug group), protodioscin group 1, protodioscin group 2, protodioscin group 3, tribulus terrestris saponin group 1, tribulus terrestris saponin group 2, tribulus terrestris saponin group 3, combination group 1, combination group 2, combination group 3, combination group 4 and combination group 5; corresponding drug treatments were added to the 12 LPS stimulation drug administration groups, and the drug treatments of each group are shown in Table 5.
[0099] Table 5. Drug administration in each group
[0100]
[0101] Note: The term “ / ” in Table 5 represents that the corresponding drug treatment was not added.
[0102] In addition, the mother solution of tribulus terrestris saponin includes tribulus terrestris saponin and DMSO. The powder of tribulus terrestris saponin is dissolved in DMSO to obtain the mother solution of tribulus terrestris saponin. The mother solutions of tribulus terrestris saponin with different concentrations (0.1 μM, 1 μM, 10 μM) can be obtained by adjusting the content of tribulus terrestris saponin.
[0103] Similarly, the protodioscin mother solution includes protodioscin and DMSO. The protodioscin mother solution can be obtained by dissolving protodioscin powder in DMSO. The protodioscin mother solution with different concentrations (10 μM, 100 μM, 1000 μM) can be obtained by adjusting the content of protodioscin.
[0104] The full English name of DMSO is Dimethyl sulfoxide, and its Chinese name is dimethyl sulfoxide.
[0105] Step S203, after the drug administration, incubate for another 1 hour, then discard the culture medium supernatant of the LPS-stimulated control group and the 12 LPS-stimulated drug administration groups, and replace them with a complete culture medium containing 125 ng / ml LPS (the culture medium is obtained by mixing LPS with the working liquid culture medium in Table 1, wherein the concentration of LPS is 125 ng / ml), and the negative control group is replaced with a complete culture medium without LPS (i.e., the working liquid culture medium in Table 1), and then continue to incubate for 24 hours before measuring the NO content of each group.
[0106] The method for testing NO content is as follows: collect the liquid in each group of culture wells into a clean EP tube, take 50ul from each well, add 50ul of 40mg / mL Griess reagent, incubate at room temperature for 30 minutes, measure the absorbance at a wavelength of 540nm, and record the experimental results.
[0107] Results and analysis of Experimental Example 2:
[0108] 1. After incubating the culture supernatant of each group with Griess reagent at room temperature for 30 minutes, observe the color reaction. Figure 3 .
[0109] Figure 3 This is a schematic diagram of the color reaction of the culture supernatant of each group with the Griess reagent after incubation at room temperature for 30 minutes.
[0110] 2. The following formula (2) was used to calculate the inflammatory clearance rate of each group except dexamethasone in the 12 LPS stimulation groups:
[0111] Formula (2): Inflammation clearance rate = (ODLPS stimulation control group - ODLPS stimulation administration group) / (ODLPS stimulation control group - OD negative control group);
[0112] In formula (2), ODLPS stimulation control group is the absorbance value of LPS stimulation control group at 540 nm, ODLPS stimulation administration group is the absorbance value of LPS stimulation administration group at 540 nm, and OD negative control group is the absorbance value of negative control group at 540 nm.
[0113] After calculation, the specific inflammation clearance rates of protodioscin groups 1-3, tribulus terrestris saponin groups 1-3 and combination groups 1-5 can be found in Figure 4 , Figure 4 This is a schematic diagram of the inflammation clearance rate of each group in Experimental Example 2.
[0114] Depend on Figure 4 It can be seen that when the addition amount of protodioscin is 10nM, it shows inhibition of the anti-inflammatory factor NO, and when the addition amount is 100nM and 1000nM, it does not show inhibition of the anti-inflammatory factor NO. When the addition amount is 1000nM, it even shows promotion of the anti-inflammatory factor NO.
[0115] When the addition amount of Tribulus terrestris saponin was 0.1nM, 1nM, and 10nM, it showed inhibition of the anti-inflammatory factor NO.
[0116] The combination of protodioscin and tribulus terrestris saponin showed the inhibition of anti-inflammatory factor NO, and the combination showed better anti-inflammatory factor NO inhibition effect than adding protodioscin or tribulus terrestris saponin alone. This shows that the composition containing protodioscin and tribulus terrestris saponin has excellent anti-inflammatory effect.
[0117] Furthermore, when the molar concentration ratio of protodioscin to tribulus terrestris saponin is 10-1000:0.1-10, the composition of protodioscin and tribulus terrestris saponin has excellent anti-inflammatory effect. The mass ratio of protodioscin to tribulus terrestris saponin is 1.7648-176.48:0.01-1 after conversion.
[0118] <Application Example 1, Emulsion>
[0119] An emulsion containing protodioscin and tribulus terrestris saponin was prepared according to the emulsion formula shown in Table 6 and the following preparation method.
[0120] The preparation method of the emulsion of Application Example 1 comprises the following steps:
[0121] Phase A is swollen evenly and heated to 80°C. Phase B is heated to 80°C. The heated phase A is added to the heated phase B and homogenized at high speed for 2-3 minutes to obtain a first mixture;
[0122] Continue to add phase C to the first mixture, stir and cool to 40° C. to obtain a second mixture;
[0123] The D phase and the E phase which were preheated to be dissolved and clear and transparent were added to the second mixture, and the mixture was homogenized and stirred to obtain an emulsion.
[0124] Table 6. Emulsion formula
[0125]
[0126] The emulsion of Application Example 1 contains protodioscin and tribulus terrestris saponin, which can inhibit the production of anti-inflammatory factor NO and has an anti-inflammatory effect.
[0127] The above specific embodiments have been described in detail for the present invention, but these do not constitute limitations on the present invention. The protection scope of the present invention is not limited to the above embodiments, and any equivalent modifications or changes made by ordinary technicians in the field based on the content disclosed by the present invention should be included in the protection scope recorded in the claims.
Claims
1. An anti-inflammatory composition, characterized in that include: Tribulus terrestris saponins and protodioscin.
2. The anti-inflammatory composition according to claim 1, characterized in that The mass ratio of the tribulus terrestris saponin to the protodioscin is 1:1-10000.
3. The anti-inflammatory composition according to claim 1, characterized in that Also included are solvents.
4. Use of tribulus terrestris saponin and protodioscin in the preparation of anti-inflammatory preparations.
5. The use according to claim 4, wherein the mass ratio of the Tribulus terrestris saponin to the protodioscin is 1:1 to 10000.
6. The use according to claim 4, wherein the anti-inflammatory preparation is used as a skin protection preparation.
7. The use according to claim 6, wherein the skin protection preparation is an external skin preparation.
8. The use according to claim 7, wherein the skin protection preparation is selected from any one of facial cream, sunscreen, milky cream, facial mask, essence, eye cream, isolation cream, liquid foundation, concealer, lotion, cleanser, toner, softener, firming lotion, lotion and body lotion.
9. An emulsion, characterized in that Includes tribulus saponins and protodioscin.
